Hongming Chen is the President and Head of R&D at METis Therapeutics, an accomplished biotech/pharmaceutical executive and serial entrepreneur known for building and leading successful organizations. He has a strong track record in developing innovative technologies/products, raising capital, and creating value for investors. Hongming has previously founded and successfully exited two biotech companies, TransForm Pharmaceuticals (acquired by J&J) and Kala Pharmaceuticals (IPO-ed). He is recognized for his contributions to the field and is a member of prestigious academies and professional organizations, including the National Academy of Engineering and the National Academy of Medicine Emerging Leaders Forum.